Raytheon awarded $71 million in Navy contracts for missile systems
Novocure Ltd (NASDAQ:NVCR) announced Thursday that it is terminating its LUNAR-4 clinical trial for metastatic non-small cell lung cancer. The decision was communicated by Novocure GmbH, a subsidiary of Novocure Ltd , to participating trial sites.
LUNAR-4 was a phase 2, single-arm, open-label, multinational study evaluating Tumor Treating Fields in combination with pembrolizumab for patients with metastatic non-small cell lung cancer who had previously received a PD-1/PD-L1 inhibitor and platinum-based chemotherapy.
According to the company’s statement, the trial was discontinued because the availability of real-world evidence will allow Novocure to achieve the objectives of the study without conducting an interventional clinical trial. Novocure stated that the decision to terminate the trial was not related to any safety concerns.
This information is based on a press release statement disclosed in a filing with the U.S. Securities and Exchange Commission. Novocure’s ordinary shares are listed on The Nasdaq Stock Market under the symbol NVCR.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.